Affordable Access

deepdyve-link
Publisher Website

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Authors
  • Nissen, Steven E
  • Wolski, Kathy
Type
Published Article
Journal
Archives of Internal Medicine
Publisher
American Medical Association
Publication Date
Jul 26, 2010
Volume
170
Issue
14
Pages
1191–1201
Identifiers
DOI: 10.1001/archinternmed.2010.207
PMID: 20656674
Source
Medline
License
Unknown

Abstract

Eleven years after the introduction of rosiglitazone, the totality of randomized clinical trials continue to demonstrate increased risk for MI although not for CV or all-cause mortality. The current findings suggest an unfavorable benefit to risk ratio for rosiglitazone.

Report this publication

Statistics

Seen <100 times